Tag: Pharmather - Page 5 - Psychedelic Alpha

Read more about the article PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021

Post published:September 8, 2021
Post category:Press Release

Read more about the article PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

Post published:July 21, 2021
Post category:Press Release

Read more about the article PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression

PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression

Post published:June 15, 2021
Post category:Press Release

Read more about the article PharmaTher Provides Research and Development Update and Milestones for 2021

PharmaTher Provides Research and Development Update and Milestones for 2021

Post published:June 10, 2021
Post category:Press Release

Read more about the article PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals

PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals

Post published:June 1, 2021
Post category:Press Release

Read more about the article PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover Novel Psychedelic Formulations

PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover Novel Psychedelic Formulations

Post published:May 27, 2021
Post category:Press Release

Read more about the article PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease

Post published:May 25, 2021
Post category:Press Release

Read more about the article Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs

Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs

Post published:May 20, 2021
Post category:Press Release

Read more about the article PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease

Post published:May 17, 2021
Post category:Press Release

Read more about the article PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™

Post published:April 27, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.